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Abstract
Background: Allergen-specific immunotherapy represents the only disease-modifying treatment for allergic
diseases. We and others have previously demonstrated that intralymphatic immunotherapy (ILIT), a less time-consuming
alternative to conventional subcutaneous immunotherapy (SCIT), is safe and effective. However, this has recently been
disputed. The aim of this study was therefore to expand our previous trial, further assessing the safety and efficacy of ILIT.
Methods: Thirty-six patients with pollen-induced rhinoconjunctivitis were randomised to receive three intralymphatic
inguinal injections of active allergen (1000 SQ-U birch- or grass-pollen) or placebo. Clinical effects, safety and circulating
immunological markers were assessed before, 4 weeks after treatment and at the end of the consecutive pollen season.
Results: No moderate or severe reactions were recorded following ILIT. Patients receiving active ILIT experienced a
significant improvement in self-recorded seasonal allergic symptoms, as compared to placebo (p = 0.05). In a subgroup
of these patients (“improved”), a reduction in nasal symptoms following nasal allergen provocation was also
demonstrated. No changes in total IgE or IgG4 were found. However, the affinity of allergen specific IgG4
following active treatment was significantly increased, as compared to non-improved patients (p = 0.04). This
could be correlated with clinical improvement, on an individual level.
Conclusions: This double-blinded placebo-controlled study confirms that ILIT is a safe and effective treatment
for pollen-induced rhinoconjunctivitis, markedly reducing seasonal allergic symptoms.
Trial registration: EudraCT: 2009-016815-39
Keywords: Allergic rhinitis, Allergen-specific immunotherapy, Intralymphatic immunotherapy, Seasonal allergisc
rhinitis, IgG4
Background
Allergic rhinitis is a growing public health problem, af-
fecting over 400 million people worldwide [1]. Currently,
allergen-specific immunotherapy (AIT) represents the
only disease-modifying treatment, diminishing symp-
toms, improving quality of life, preventing new sensiti-
sations and reducing the risk of asthma development
[2, 3]. The golden standard treatment is subcutaneous
immunotherapy (SCIT), which shows long-term benefit
for the treatment of allergic rhinitis, conjunctivitis and
asthma [3, 4]. Despite this, only 5 % of patients undergo
this therapy, due to frequent injections, risk of adverse
effects and the long duration of treatment [2]. A more
recent, non-invasive route of administration is sublin-
gual immunotherapy (SLIT). Though efficacious, SLIT
is associated with reduced compliance due to the long
period of self-medication [5].
Intralymphatic immunotherapy (ILIT) is an emerging
form of AIT that involves three injections of allergen
over a period of 12 weeks. This form of AIT directs
lower doses of allergen to the highly immunocompetent
lymph node, in an effort to maximise chances for
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tolerance induction, while minimising the risk for ad-
verse effects. In the pioneering study in 2008, ILIT was
shown to induce long-lasting allergen tolerance, equiva-
lent to that of SCIT, but with fewer adverse events [6].
Since then, ILIT has demonstrated clinical efficacy
against allergy to cat dander and, recently, against grass-
pollen induced rhinoconjunctivitis in adolescents and
young adults [7, 8].
In a recent small double-blind placebo controlled study,
we too demonstrated that ILIT against grass pollen re-
sulted in a significant improvement of patient-recorded
symptoms during the pollen season, while injection-
associated discomfort levels were comparable to that of
SCIT [9]. However, the clinical efficacy of ILIT is currently
disputed [10]. Consequently, the aim of the present study
was to expand our first trial to determine if the safety and
efficacy of ILIT persisted in a larger cohort of patients.
Methods
Study population and eligibility criteria
Study subjects were recruited amongst patients at the al-
lergy department of Skåne University Hospital, Malmö,
Sweden. Eligible patients were aged between 18 and 65
and had moderate to severe allergic birch/grass pollen-
induced rhinoconjunctivitis, with symptoms including
itchy nose and eyes, sneezing, nasal congestion and
secretion. Allergy was verified by positive skin prick tests
(SPTs), presence of serum-specific IgE antibodies to-
wards birch and/or grass (minimum 0.35 kU/L) and
positive nasal provocation tests (NPTs). Sample size was
based on our previous study [9]. All eligible participants
recruited during the recruitment period were enrolled in
the study.
General contraindications were pregnancy or nursing,
planning for pregnancy, autoimmune and collagen
disease, cardiovascular disease, current persistent asthma
(not intermittent asthma), upper airway disease (non-al-
lergic sinusitis, nasal polyps), chronic obstructive and
restrictive lung disease, hepatic and renal disease, cancer,
previous immune- or chemotherapy, major metabolic
disease, alcohol or drug abuse, mental incapability (to
cope with the study) or medication with a possible side-
effect of interfering with the immune response.
Study design
This study was a parallel double-blind placebo-controlled
trial, performed at the allergy department of Skåne
University Hospital, Malmö, Sweden.
In total 36 patients were enrolled. Fifteen patients
were recruited in the first cohort (September 2010 to
September 2011) and have been previously defined [9].
Twenty-one patients were recruited in the second cohort
(September 2011 to September 2012).
At the first visit (visit 1, out of pollen season, 2010 or
2011), patient eligibility was determined, SPTs and NPTs
were performed and blood was sampled (further details
in Additional file 1). After approximately one week, in-
cluded patients were randomly allocated to receive ei-
ther placebo (n = 15) or active (n = 21) intralymphatic
treatment. At visits 2–4 (September 2010 – January
2011 or September 2011 – January 2012), the study sub-
jects received three 0.1 ml injections with either placebo
(Alutard, ALK Abéllo, Horsholm, Denmark) or 1000
SQ-U of standardised, aluminium hydroxide adsorbed,
depot birch- or grass-pollen vaccine (Alutard, ALK
Abéllo) at 3- to 4-week intervals. Based on the outcome
of the allergy tests, patients were challenged and vacci-
nated with either birch or grass (mono-sensitised).
Patients returned approximately 4 weeks after the last
injection (visit 5, February 2011 or February 2012) and
after the consecutive pollen season (visit 6, September
2011 or September 2012), and were evaluated as per visit
1. At visit 6, patients were additionally asked to complete
a questionnaire regarding their seasonal allergic symptoms
as compared to the previous pollen season. One patient
did not complete the treatment, due to a non-severe
adverse event (local urticaria). Emergency envelopes
remained unbroken.
Randomisation, allocation and blinding
Participants were randomly assigned to one of two treat-
ment groups following a simple randomisation proced-
ure with opaque, sealed envelopes. The randomisation
procedure was generated by independent biomedical as-
sistants. The vaccines used were pre-packed, blinded
and allocated according to the randomisation sequence
by independent staff with no connection to the study,
and thus both patients and physicians were blind. Re-
cruitment was performed by UPW. All those involved in
the study, including participants, care-givers and those
assessing outcomes, were blinded after assignment to
interventions.
Ethics, consent and permissions
The study was approved by the local ethics committee
(ref. ID 2009/714) and all participants gave their written
informed consent.
Intralymphatic injections
A superficial inguinal lymph node in either the left or
right groin was aseptically injected using a 25-gauge
needle and ultrasound guidance. The superficial lymph
nodes in the groin were identified as hypoechoic nod-
ules with a diameter of 0.5 to 1.5 cm. The same side
and, as far as possible the same node, was targeted dur-
ing all three injections. Aspirations were made before
the injections to avoid inadvertent intravascular
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administration. The peak expiratory flow (PEF) was
measured before and after each injection, and all pa-
tients were monitored at the ward for no less than
60 min after each injection. The trial staff recorded all
signs of local and/or systemic reactions in conjunction
with the injections. The patients were subsequently
asked to record and report all indications of late reac-
tions for the following 24 h.
Trial outcomes
Primary outcome measures
The primary outcome measure for the study was the
change in pollen season-associated allergic symptoms.
At the end of the first allergy season, after treatment had
been given (visit 6), patients were asked to compare their
most recent seasonal allergic symptoms with the symp-
toms they experienced during the pollen season prior to
treatment. To this end, a visual analogue scale (VAS),
ranging from 0 (unchanged symptoms, no improvement)
to ten (total symptom relief, complete recovery), was
used, as previously described [11].
Secondary outcome measures
The secondary outcome measures of the study were 1)
the safety of intralymphatic injections; 2) the change in
nasal symptom score (NSS) following NPT (comparisons
of NSS after NPT before treatment, after treatment and
after the consecutive pollen season), as previously de-
scribed [9]; 3) the change in circulating immunoglobulin
(IgE and IgG4) levels (comparisons of levels before treat-
ment, after treatment and after the consecutive pollen
season); and 4) change in circulating inflammatory cells
(comparisons of levels before treatment, after treatment
and after the consecutive pollen season).
Additional secondary outcomes
Blood samples acquired at visit 6 (after the pollen season
following treatment) were re-analysed following unblind-
ing of the study, to determine alterations in IgG4 affinity.
This was due to the appearance of two distinct sub-
populations in the active ILIT group (“improved” and
“non-improved”; see Results), which demonstrated no
difference in IgG4 levels. Further analysis was conse-
quently performed, with the aim to immunologically dis-
criminate between these groups.
Tertiary outcomes
As a tertiary outcome, patients were asked to report
their usage of allergy medication during the pollen sea-
son immediately after ILIT, with their use in the allergy
season prior to the start of treatment. Patients were
asked to report a reduction in use, an increase in use or
a no change in use, in terms of their use of anti-
histamines, corticosteroid nasal spray and eye drops.
Methods used for assessment of secondary and
additional trial outcomes
Methods used for the assessment of trial outcomes,
including nasal provocation test, flow cytometry, and
assessment of IgG4 affinity can be found in the sup-
plementary material (Additional file 1).
Statistical analysis
Statistical analysis was performed using GraphPad Prism
5.01 software (San Diego, CA, USA). Distribution of data
was assessed using the D’Agostino and Pearson omnibus
normality test. Parametric data was analysed using a
Student’s unpaired t-test (unpaired observations) or
repeated measures ANOVA followed by Dunnet’s
multiple comparison post-test (paired observations).
Non-parametric paired observations were analysed
using the Friedman test, followed by Dunn’s multiple
comparison post-test. IgG4 affinity was analysed by
two-way ANOVA, followed by the uncorrected Fisher’s
LSD test. Correlation was determined by calculating the
Pearson’s correlation coefficient. Data are represented as




A flow-diagram showing enrolment/screening, alloca-
tion, and patient follow-up is depicted in Fig. 1. Thirty-
six participants were screened between September 2010
and September 2011. They all demonstrated positive
SPT, NPT and serum IgE and were therefore enrolled in
the trial. Fifteen patients were enrolled in September
2010 [9]; 21 patients were enrolled in September 2011.
Twenty-one patients received active ILIT (seven in the
2010 study, 14 in the 2011 study) and 15 patients re-
ceived placebo (eight in the 2010 study, seven in the
2011 study). One patient receiving active ILIT demon-
strated localised urticaria following the first intralympha-
tic injection and did not wish to further participate in
the study. The demographics of participants are depicted
in Table 1.
Primary End-Point
At the end of the pollen season following treatment,
subjects were asked to compare their seasonal allergic
symptoms with the allergic season prior to the start
of treatment. A clear improvement in relation to
baseline was observed in the active ILIT group (VAS-
score: 4.78 ± 0.9) (Fig. 2). This improvement was sig-
nificantly more marked than the effects recorded in
the placebo group (p = 0.047). However, no substantial
reduction in medication could be verified in the ac-
tive ILIT group (Additional file 2).
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Evaluation of treatment outcome additionally resulted
in the emergence of two clear sub-populations among
the patients who received active ILIT: one group of 12
patients that reported a clear improvement in symptoms
(VAS-score > 5) and a group of 8 patients that reported
no improvement (VAS-score < 1) (Fig. 2). No patients re-
ported a VAS-score between 1 and 5.
Secondary End-Point
Safety assessment of intralymphatic allergen administration
The number of local drug-related reactions (e.g. lymph
node swelling, itch and redness close to the proximity of
the injection site) was higher in the active group than in
the placebo group. One patient recorded mild side-
effects at the first injection (localised redness and urti-
caria), which resulted in the individual’s withdrawal from
the study. However, no moderate or severe reactions
were recorded (Table 2). At the follow-up visit, approxi-
mately 4 weeks after the final injection, all drug-related
reactions were resolved.
Circulating immunological markers
No significant differences in total serum levels of IgE or
IgG4 were evident in the active ILIT group or placebo
group (Fig. 3). In addition there was no significant
increase in CD4+CD25+FoxP3+ lymphocytes in the ac-
tive ILIT or placebo group (data not shown).
Nasal symptom scores
No significant change in NSS following NPT could be
seen in the active ILIT or placebo groups (data not
shown). However, nine out of 12 patients in the active
ILIT group with a VAS-score over five demonstrated a
Fig. 1 Flow diagram of study cohort. ILIT: Intralymphatic immunotherapy
Table 1 Baseline characteristics of patients included in the
study
Active ILIT Placebo ILIT
Number of participants 21 15
Age (y), median (range) 30 (20–52) 30 (20–54)
Gender (male vs. female) 13:8 9:6
Allergen-specific IgE (kU/L) 4.4 – 100.0 0.47 – 78.6


































10  complete recovery
 no improvement
*
Fig. 2 Patient-recorded treatment outcome following three
intralymphatic injections with active ILIT or placebo. Patients compared
seasonal allergic symptoms after treatment, with symptoms prior to
treatment. A VAS-score of 0 indicates no improvement, whereas a
score of 10 indicates complete recovery. The black box signifies
“improved” patients with a VAS-score above 5; the grey box signifies
“non-improved” patients with a VAS-score below 1. Circles represent
patients with an allergy towards birch pollen; triangles represent
patients with an allergy towards grass pollen. *p < 0.05 using an
Unpaired t test. ILIT: Intralymphatic immunotherapy
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reduction of allergic symptoms upon NPT after treat-
ment (“improved” sub-population). In contrast, seven
out of eight patients in the active ILIT group with a
VAS-score under 1 demonstrated no reduction of aller-
gic symptoms upon NPT after treatment (“non-im-
proved” sub-population) (Fig. 4a).
Further analysis revealed that improved patients dem-
onstrated a reduction in NSS following NPT 4 weeks
after treatment (p = 0.014) and after the consecutive
pollen season (p = 0.015) (Fig. 4b). These reductions
were not evident in the eight non-improved patients, or
in the placebo group. In contrast, an increase in NSS
following NPT was evident in non-improved patients,
after the consecutive pollen season (p = 0.011)
“Improved” vs “Non-improved” IgG4 levels and IgG4 affinity
Analysis of IgG4 levels in the nine improved and 8 non-
improved patients, as well as the placebo group, revealed
no changes in levels of IgG4 before treatment, after treat-
ment and after the consecutive pollen season (Fig. 5a).
In contrast, analysis of IgG4 affinity in samples taken
after the consecutive pollen season demonstrated that
allergen-specific IgG4 affinity was significantly increased
in improved patients (p = 0.035), as compared to non-
improved patients (Fig. 5b).
In addition, a significant and positive correlation be-
tween IgG4 and both VAS score (r
2 = 0.42, p = 0.04) and
reduction in nasal symptom score (r2 = 0.48, p = 0.03)
was found.
Tertiary End-Point
No substantial reduction in medication (anti-histamines,
local nasal steroids) could be verified in the active ILIT
group (Additional file 2).
However, improved patients reported a reduction in
the use of all allergy medication in the allergy season
following treatment. This was not evidenced in the
non-improved, actively treated patients. Improved pa-
tients demonstrated a stronger reduction in the use
of corticosteroid nasal spray and eye drops, but not
anti-histamines, as compared to the placebo group
(Additional file 2).
Discussion
In a recent study, we demonstrated that ILIT is a safe
and effective administration route for the induction of
allergen tolerance and treatment of nasal allergic inflam-
mation [9]. In the present study, we have added a new
cohort of study subjects and together they reinforce the
hypothesis that ILIT is effective in reducing allergic
Table 2 Adverse events associated with intralymphatic injections
Active ILIT (61 injections) Placebo ILIT (45 injections)
Early Reactions Late Reactions Early Reactions Late Reactions
Local Lymph Node Swelling Mild: 6 Mild: 14 Mild: 1 Mild: 1
Moderate: 0 Moderate: 0 Moderate: 0 Moderate: 0
Severe: 0 Severe: 0 Severe: 0 Severe: 0
Local Itch Mild: 6 Mild: 11 Mild: 2 Mild: 1
Moderate: 0 Moderate: 0 Moderate: 0 Moderate: 0
Severe: 0 Severe: 0 Severe: 0 Severe: 0
Local Redness Mild: 11 Mild: 21 Mild: 0 Mild: 0
Moderate: 0 Moderate: 0 Moderate: 0 Moderate: 0
Severe: 0 Severe: 0 Severe: 0 Severe: 0
Nasal Symptoms Mild: 1 Mild: 1 Mild: 4 Mild: 4
Moderate: 0 Moderate: 0 Moderate: 0 Moderate:0
Severe: 0 Severe: 0 Severe: 0 Severe: 0
Pulmonary Symptoms Mild: 0 Mild: 0 Mild: 0 Mild: 0
Moderate: 0 Moderate: 0 Moderate: 0 Moderate: 0
Severe: 0 Severe: 0 Severe: 0 Severe: 0
Urticaria and angiooedema Mild: 1 Mild: 4 Mild: 0 Mild: 1
Moderate: 0 Moderate: 0 Moderate: 0 Moderate: 0
Severe: 0 Severe: 0 Severe: 0 Severe: 0
Abdominal Symptoms Mild: 0 Mild: 1 Mild: 0 Mild: 1
Moderate: 0 Moderate: 0 Moderate: 0 Moderate: 0
Severe: 0 Severe: 0 Severe: 0 Severe: 0
Hylander et al. Respiratory Research  (2016) 17:10 Page 5 of 9
symptoms and that it is not associated with severe ad-
verse events. In addition, we highlight a role for in-
creased allergen-specific IgG4 affinity in successful ILIT.
During the past few years, ILIT has come forward as
a less time-consuming and more cost-effective alterna-
tive to conventional subcutaneous allergen-specific im-
munotherapy (SCIT) for treatment of pollen-induced
rhinoconjunctivitis. It has provided promising clinical
results in combination with an excellent safety profile
[6, 9], likely related to the drastic reduction in amount
of administered allergen. This present study de-
monstrates that, as compared to placebo, active ILIT
treatment results in improvement of seasonal allergic
symptoms, without any moderate or severe adverse re-
actions. This study further supports ILIT as a safe and
effective treatment strategy for patients with pollen-
induced rhinoconjunctivitis. Indeed, the 60 % success
rate is comparable to the approximate 70 % success rate
for SCIT [12]. Although it is evident that five out of
eight placebo patients responded to treatment, it is
worth noting that the number needed to treat (NNT)
value for ILIT, which takes into account responders and
non-responders in both active and placebo groups, is
7.5. This NNT value is much lower than those calcu-
lated for more common treatments of allergic rhinitis,
such as anti-histamines [13].
The somewhat lower success rate of ILIT as compared
to SCIT may be related to the technical aspects of aller-
gen injections. Unlike SCIT, ILIT uses complex medical
equipment and involves higher technical precision, as
targeted nodes are relatively small (0.5–1.5 cm). Despite
the use of a fine needle and ultrasound guidance, it can
on occasion be difficult to penetrate the capsule sur-
rounding the lymph node, which may lead to inadequate
administration of allergen.
Despite repeated promising results, the overall effi-
cacy of ILIT against grass-pollen-induced allergic rhin-
itis has recently been questioned [10]. In a double-blind
placebo-controlled trial, 15 patients receiving active
ILIT against grass pollen showed immunological indica-
tions of tolerance, but no clinical improvement. As
recently argued [14, 15], these results were likely due to
the interval between injections. Witten et al [10]
injected allergen every 2 weeks, which, unlike a 4-week
interval, does not allow sufficient time for the develop-
ment of non-interfering waves of antigen-specific immune
responses [16]. The present study, where injections were
given at 4-week intervals, again highlights the importance
of correct time interval between injections.
In this study, two distinct sub-populations could be
observed among the actively treated patients. Patients in
the first sub-population reported a clear improvement of
their allergic symptoms, as characterised by reduced
nasal allergen reactivity, decreased usage of allergy medi-
cation (anti-histamines, local steroids, eye drops) and
self-recorded improvement (VAS-scale). In contrast, pa-
tients in the second sub-population experienced no reso-
lution of symptoms. The reason for the emergence of
two sub-populations is unknown and may, at least in
part, be related to technical difficulties during intra-
lymphatic injection, resulting in extra-nodal deposits of
allergen and an ineffective tolerance induction. Never-
theless, the sub-populations firstly demonstrate the use-
fulness of the nasal provocation test (NPT) as a read-out
of clinical efficacy, as nine out of 12 patients with self-
reported improvement in season allergic symptoms
(VAS-scale) also reported a reduction in symptoms
following NPT. Secondly, these populations give in-
sights into the underlying immunological mechanisms
associated with efficacious ILIT.
The present study, as well as the aforementioned study
by Witten et al [10], both suggest that immunological al-























































































































Fig. 3 Levels of circulating immunoglobulins. IgE (a-b) and IgG4
(c-d) were measured before treatment, four weeks after treatment and
after the consecutive pollen season in patients treated with active ILIT
(a, c) or placebo (b, d). Analysis was performed using a repeated
measures ANOVA. ILIT: Intralymphatic immunotherapy
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elevated T-regulatory cells and cytokines, and IgG4 levels
in blood, are not prerequisites for clinical efficacy of
ILIT. Witten et al [10] noted increases in T-regulatory
cells, IL-10 production and IgG4 following active ILIT,
but demonstrated no clinical improvement when com-
pared to placebo. In contrast, we demonstrated clinical
improvement in the absence of increases in circulating
T-regulatory cells and total serum IgG4. The reason for
this is unclear, but may be related to the short time
interval between vaccination and blood sampling. How-
ever, we demonstrated that clinical improvement was as-
sociated and significantly correlated with increased
allergen-specific IgG4 affinity. Indeed, as previously sug-
gested [14] affinity of B- and T-cell receptors is likely a
very important parameter for the induction of tolerance
to allergen and subsequent efficacious therapeutic
responses.
There is an intricate interaction between B- and T-
cells in the specialised lymph node compartment. B-cells
bind the injected allergen via the cell-surface B-cell re-
ceptor (BCR), which leads to receptor mediated endo-
cytosis, processing and peptide loading. Subsequently,
allergen-derived peptides are presented via the MHC
class II pocket to allergen-specific CD4+ T-helper cells.
This B-cell induced activation of T-cells, reciprocally, al-
lows for T-helper cell-licensed class switching and affin-
ity maturation of IgG [17]. In the case of the present
































































































































































Fig. 4 Identification and nasal symptom scores of improved and non-improved patients. a Identification of patients reporting change in allergic
symptoms 30 min after nasal allergen provocation (NPT), as well as change of seasonal allergic symptoms (VAS-score 0 = no improvement;
VAS-score: 10 = complete recovery) after treatment. “Improved” patients are depicted with a black box. Non-improved patients are depicted with a
grey box. b Self-reported allergic symptoms 30 min after nasal allergen provocation before treatment, four weeks after treatment and following the
consecutive pollen season in improved, non-improved and placebo patients *p < 0.05 using a repeated measures ANOVA followed by a Dunnet’s
multiple comparison post-test. ILIT: Intralymphatic immunotherapy
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affinity of IgG4, avoiding IgE production. The reason for
IgG4 preferences in the present study is likely the use of
adjuvant, as well as the compartment for the delivery of
allergens, lymph nodes being more prone to IgG responses,
as compared to airway responses to pollen allergens.
Furthermore, competition for antigen, which occurs
more effectively when low concentrations of antigen is
present in lymph follicles, is vital for the positive selection
of high affinity B-cells, and this phenomenon has similarly
been suggested for selection of high affinity T-cells [18].
This suggests that a 2-week-interval between injections,
where concentrations of allergen in lymph nodes is con-
sistently high, may induce clear B- and T-cell responses,
as seen by increased serum levels of total IgG4 levels and
allergen-induced intracellular T-cell cytokine production
[10], but with a low affinity maturation, resulting in poor
clinical efficacy. Indeed, previous studies have noted that
functionality of IgG4, rather than levels, more closely re-
late to clinical efficacy in AIT [19, 20]
Although this study clearly indicated that ILIT does
improve clinical symptoms of pollen-induced rhinocon-
junctivitis, particularly in the improved sub-population,
there are a number of limitations. Firstly, the use of a
VAS scale for patient recorded outcome has been de-
bated, in particular in long-term studies, due to recall
bias. However, several publications have demonstrated
that using VAS to measure self-recorded outcome
following immunotherapy parallels the more objective,
and more regularly monitored, symptom and medication















































































































































Fig. 5 Change in IgG4 levels and affinity in improved and non-improved patients. a Levels of circulating IgG4 in improved and non-improved
actively treated patients, as well as placebo patients, before treatment, four weeks after treatment and following the consecutive pollen season.
Analysis was performed using a repeated measures ANOVA. b IgG4 affinity in improved and non-improved patients, measured and presented as
percent allergen-bound IgG4 with increasing concentrations of ammonium thiocyanate (NH4SCN). n = 3–7 *p < 0.05 using two-way ANOVA
followed by Fisher’s LSD
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In addition, with the small sample size of 35 patients used
in this study, it is impossible determine whether ILIT is an
effective treatment for the general allergic population.
However, previous studies with smaller [9] and larger [6]
sample sizes show similar effects, which suggests that ILIT
has a generalised efficacy. Further, as this study only spanned
over one year, long-term efficacy of ILIT is unknown.
Nevertheless, previous studies have demonstrated that
efficacy of ILIT against grass-pollen-induced rhinoconjunc-
tivitis persists for at least 3 years following treatment [6].
Conclusions
This double-blind placebo-controlled trial adds to the
existing literature and provides further evidence that
ILIT is a safe and effective treatment for pollen-induced
allergic rhinitis. ILIT circumvents the drawbacks typic-
ally associated with SCIT, namely the frequent injec-
tions, high risk for adverse events and long duration of
treatment, and may therefore represent a novel lower-
cost form of AIT. However, larger and longer-term
studies, investigating efficacy as well as immunological
mechanisms are required to optimise the ILIT treatment
regimes. Nonetheless, the present study lends further
support for ILIT being a future safe and effective form
of AIT. In addition, the data presented suggests that
NPT and high affinity allergen-specific IgG4 may be
valuable predictors for the efficacy of ILIT. If so, this
represents a simple way to evaluate the long-term per-
sistence of symptom-reducing effects of ILIT.
Additional files
Additional file 1: Supplementary Methods. Additional methods not
provided in the main text. (DOCX 20 kb)
Additional file 2: Supplementary Data. Two tables depicting change
in medication use in active and placebo ILIT groups, as well as improved
and non-improved sub-groups. (DOCX 16 kb)
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
TH was involved in study design and responsible for acquisition, analysis and
interpretation of data, as well as drafting of the manuscript. OL was involved
in analysis and interpretation of data, as well as drafting of the manuscript.
UPW was involved in study design, coordination of study and acquisition of
data. ME was involved in acquisition of data. SKG was involved in coordination
of the study, interpretation of data and drafting of the manuscript. LOC
designed and coordinated the study, was involved in interpretation of data and
drafting of the manuscript. All authors read and approved the final manuscript.
Acknowledgements
The authors would like to thank Anna Karin Bastos, Josefine P Rikonen, Eva
Thylander and Ronia Ravazi for logistic and technical support.
Author details
1Division of ENT Diseases, Department of Clinical Sciences, Intervention and
Technology, Karolinska Institutet, Stockholm, Sweden. 2Laboratoy of Clinical
Experimental Allergy Research, Department of Otorhinolaryngology Malmö,
Lund University, Skåne University Hospital, Malmö, Sweden. 3Department of
ENT Diseases, Karolinska University Hospital, Stockholm, Sweden.
4Department of Medicine Solna, Translational Immunology Unit, Karolinska
University Hospital Solna, Stockholm, Sweden.
Received: 9 September 2015 Accepted: 13 January 2016
References
1. Bousquet J, Dahl R, Khaltaev N. Global alliance against chronic respiratory
diseases. Allergy. 2007;62:216–23.
2. Frew AJ. 25. Immunotherapy of allergic disease. J Allergy Clin Immunol.
2003;111:S712–9.
3. Akdis CA, Akdis M. Advances in allergen immunotherapy: aiming for
complete tolerance to allergens. Sci Transl Med. 2015;7:280ps286.
4. Akdis M, Akdis CA. Mechanisms of allergen-specific immunotherapy.
J Allergy Clin Immunol. 2007;119:780–91.
5. Werner-Klein M, Kalkbrenner F, Erb KJ. Sublingual immunotherapy of allergic
diseases. Expert Opin Drug Deliv. 2006;3:599–612.
6. Senti G, Prinz Vavricka BM, Erdmann I, Diaz MI, Markus R, McCormack SJ,
et al. Intralymphatic allergen administration renders specific immunotherapy
faster and safer: a randomized controlled trial. Proc Natl Acad Sci U S A.
2008;105:17908–12.
7. Senti G, Crameri R, Kuster D, Johansen P, Martinez-Gomez JM, Graf N, et al.
Intralymphatic immunotherapy for cat allergy induces tolerance after only 3
injections. J Allergy Clin Immunol. 2012;129:1290–6.
8. Patterson AM, Bonny AE, Shiels WE 2nd, Erwin EA. Three-injection
intralymphatic immunotherapy in adolescents and young adults with grass
pollen rhinoconjunctivitis. Ann Allergy Asthma Immunol 2015. doi:10.1016/j.
anai.2015.11.010.
9. Hylander T, Latif L, Petersson-Westin U, Cardell LO. Intralymphatic
allergen-specific immunotherapy: an effective and safe alternative
treatment route for pollen-induced allergic rhinitis. J Allergy Clin
Immunol. 2013;131:412–20.
10. Witten M, Malling HJ, Blom L, Poulsen BC, Poulsen LK. Is intralymphatic
immunotherapy ready for clinical use in patients with grass pollen allergy?
J Allergy Clin Immunol. 2013;132:1248–52. e1245.
11. Makatsori M, Pfaar O, Calderon MA. Allergen immunotherapy: clinical
outcomes assessment. J Allergy Clin Immunol Pract. 2014;2:123–9. quiz 130.
12. Kundig TM. Immunotherapy concepts under investigation. Allergy. 2011;66
Suppl 95:60–2.
13. Portnoy JM, Van Osdol T, Williams PB. Evidence-based strategies for
treatment of allergic rhinitis. Curr Allergy Asthma Rep. 2004;4:439–46.
14. Kundig TM, Johansen P, Bachmann MF, Cardell LO, Senti G. Intralymphatic
immunotherapy: time interval between injections is essential. J Allergy Clin
Immunol. 2014;133:930–1.
15. Hjalmsdottir A, Wackerle-Men Y, Duda A, Kundig TM, Johansen P. Dosing
intervals in intralymphatic immunotherapy. Clin Exp Allergy 2015. doi:10.
1111/cea.12657.
16. Siegriest C. Vaccine Immunology. In: Vaccines. 6 ed. Philadelphia: Elsevier;
2013: 14-32.
17. Akdis CA, Akdis M. Mechanisms of allergen-specific immunotherapy and
immune tolerance to allergens. World Allergy Organ J. 2015;8:17.
18. Kedl RM, Kappler JW, Marrack P. Epitope dominance, competition and T cell
affinity maturation. Curr Opin Immunol. 2003;15:120–7.
19. Shamji MH, Ljorring C, Francis JN, Calderon MA, Larche M, Kimber I, et al.
Functional rather than immunoreactive levels of IgG4 correlate closely with
clinical response to grass pollen immunotherapy. Allergy. 2012;67:217–26.
20. Wachholz PA, Durham SR. Mechanisms of immunotherapy: IgG revisited.
Curr Opin Allergy Clin Immunol. 2004;4:313–8.
21. Pozzan M, Milani M. Efficacy of sublingual specific immunotherapy in
patients with respiratory allergy to Alternaria alternata: a randomised,
assessor-blinded, patient-reported outcome, controlled 3-year trial. Curr
Med Res Opin. 2010;26:2801–6.
22. Ariano R, Kroon AM, Augeri G, Canonica GW, Passalacqua G. Long-term
treatment with allergoid immunotherapy with Parietaria. Clinical and
immunologic effects in a randomized, controlled trial. Allergy. 1999;54:
313–9.
23. Senti G, von Moos S, Tay F, Graf N, Sonderegger T, Johansen P, et al.
Epicutaneous allergen-specific immunotherapy ameliorates grass pollen-
induced rhinoconjunctivitis: a double-blind, placebo-controlled dose
escalation study. J Allergy Clin Immunol. 2012;129:128–35.
Hylander et al. Respiratory Research  (2016) 17:10 Page 9 of 9
